The FDA granted orphan designation to Unicycive Therapeutics’ treatment for the prevention of delayed graft function in patients undergoing solid organ transplantation, according to a post to the agency’s website.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on UNCY:
- Unicycive Therapeutics Averts Nasdaq Delisting Concerns
- Unicycive Therapeutics initiated with an Outperform at Noble Capital
- Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
- Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
- Unicycive Therapeutics issues letter to shareholders
